Top Markets
Coin of the day
China Resources Double-Crane Pharmaceutical Co.,Ltd. China Resources Double-Crane Pharmaceutical Co.,Ltd.

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062
Rang in Aktien #5801
China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its... China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its affiliated companies, operates as a prominent pharmaceutical enterprise within the People's Republic of China. The company's diverse product range includes various types of infusion solutions, available in soft bags, plastic and glass bottles, as well as inner-sealed and blend polypropylene bags. Its manufacturing capabilities extend to numerous injectable products, such as levofloxacin methylate, ambroxol hydrochloride glucose, fructose, invert sugar, hydroxyethyl starch, and sodium chloride injections, among others. Additionally, it supplies vital dialysate solutions for both peritoneal and hemodialysis. A substantial part of its portfolio is dedicated to addressing cardiovascular and cerebrovascular diseases, featuring medications like compound reserpine triamterene tablets, pitavastatin calcium tablets, telmisartan capsules, suppository capsules, banidipine hydrochloric acid sustained-release capsules, and edaravone. Furthermore, China Resources Double-Crane offers treatments for endocrinological conditions and a selection of pediatric drugs, notably including pediatric compound amino acid injections. The company's offerings also encompass nutritional supplements, such as vitamins E and C, and a variety of anti-infective pharmaceuticals. Headquartered in Beijing, the People's Republic of China, China Resources Double-Crane Pharmaceutical Co.,Ltd. is an affiliate of Beijing Pharmaceutical Group Co., Ltd.
Aktienkurs
$2.34
Marktkapitalisierung
$2.43B
Veränderung (1 Tag)
-0.37%
Veränderung (1 Jahr)
-14.62%
Land
CN
Handel China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062)

Kategorie

P/B-Verhältnis für China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von China Resources Double-Crane Pharmaceutical Co.,Ltd. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für China Resources Double-Crane Pharmaceutical Co.,Ltd. von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber